AU4923696A - Lipid constructs for cytoplasmic delivery of agents - Google Patents

Lipid constructs for cytoplasmic delivery of agents

Info

Publication number
AU4923696A
AU4923696A AU49236/96A AU4923696A AU4923696A AU 4923696 A AU4923696 A AU 4923696A AU 49236/96 A AU49236/96 A AU 49236/96A AU 4923696 A AU4923696 A AU 4923696A AU 4923696 A AU4923696 A AU 4923696A
Authority
AU
Australia
Prior art keywords
agents
lipid constructs
cytoplasmic delivery
cytoplasmic
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49236/96A
Inventor
Roxanne Male-Brunne
Richard Proffitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexstar Pharmaceuticals Inc
Original Assignee
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc
Publication of AU4923696A publication Critical patent/AU4923696A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01028—Chloramphenicol O-acetyltransferase (2.3.1.28)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
AU49236/96A 1995-02-10 1996-02-08 Lipid constructs for cytoplasmic delivery of agents Abandoned AU4923696A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38657795A 1995-02-10 1995-02-10
US386577 1995-02-10
PCT/US1996/001960 WO1996024334A1 (en) 1995-02-10 1996-02-08 Lipid constructs for cytoplasmic delivery of agents

Publications (1)

Publication Number Publication Date
AU4923696A true AU4923696A (en) 1996-08-27

Family

ID=23526179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49236/96A Abandoned AU4923696A (en) 1995-02-10 1996-02-08 Lipid constructs for cytoplasmic delivery of agents

Country Status (2)

Country Link
AU (1) AU4923696A (en)
WO (1) WO1996024334A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
AU7596496A (en) * 1995-10-19 1997-05-07 Johnson & Johnson Interventional Systems Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia
FR2764304B1 (en) * 1997-06-06 1999-07-16 Rhone Poulenc Rorer Sa NEW CLASS OF CATIONIC NUCLEIC ACID TRANSFECTANTS
US20020058795A1 (en) * 1997-09-08 2002-05-16 Russ J. Mumper Hydrophobic glycosylamine derivatives, compositions, and methods for use
FR2829136B1 (en) * 2001-08-29 2006-11-17 Aventis Pharma Sa LIPID DERIVATIVES OF AMINOGLYCOSIDES
ATE430758T1 (en) * 2001-08-29 2009-05-15 Aventis Pharma Sa LIPID-AMINOGLYCOSIDE CONJUGATES FOR TRANSFECTION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310505A (en) * 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
CA2153158A1 (en) * 1993-01-07 1994-07-21 Andrew Zalewski Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells

Also Published As

Publication number Publication date
WO1996024334A1 (en) 1996-08-15

Similar Documents

Publication Publication Date Title
AU6527596A (en) Lipid vehicle drug delivery composition containing vitamin e
AU5979296A (en) Peptide-enhanced cationic lipid transfections
AU5928696A (en) Intracellular delivery of macromolecules
AU5869796A (en) Micromechanical patch for enhancing the delivery of compound s through the skin
AU7606696A (en) Selective advertisement presentation
HUP9802095A3 (en) Stabilized gasemulsion containing phospholipid for ultrasound contrast enhancement
AU7450196A (en) Device for delivering biological agents
AU7010496A (en) Composition for sustained release of an agent
AU6385396A (en) Drug mitochondrial targeting agents
AU696092B2 (en) Estimation of excitation parameters
AU5153296A (en) Vectors for gene delivery
AU1403199A (en) Local delivery of therapeutic agents
AU6558296A (en) Buccal delivery system for therapeutic agents
AU4892897A (en) Phospholipid drug derivatives
AU4265496A (en) Perhydroisoindole derivatives as antagonists of substance p
AU4778196A (en) Hydrosilylation of unsaturated compounds
AU5539596A (en) Anti-obesity agents
AU5022096A (en) Lipid constructs for targeting to vascular smooth muscle tissue
AU6165196A (en) Stable formulations of mhc-peptide complexes
AU6679296A (en) Hepadnavirus receptor
AU8028898A (en) Internally supported lipid vesicle systems
AU694663B2 (en) Agents for use against parasitic protozoa
AU1166097A (en) Indoloquinone derivatives as bioreductive agents
AU4923696A (en) Lipid constructs for cytoplasmic delivery of agents
AU6940998A (en) Phospholipid drug derivatives